Table 2 Neurologic characteristics of 53 patients with DPPX antibodies
No. (%) | |||
|---|---|---|---|
Previous reported (n = 44) | Ours (n = 9) | Sum (n = 53) | |
Characteristics | |||
Cognitive disorders | 32 (72.7) | 7 (77.8) | 39 (73.6) |
Brainstem or spinal cord disordersa | 36 (81.8) | 4 (44.4) | 40 (75.5) |
Cerebellar ataxia | 16 (36.4) | 2 (22.2) | 18 (34.0) |
Myoclonus or tremor | 23 (52.3) | 3 (33.3) | 26 (49.1) |
Limb paralysis | 0 (0) | 2 (22.2) | 2 (3.8) |
Psychosisb | 14 (31.8) | 1 (11.1) | 15 (28.3) |
Headache | 1 (2.3) | 5 (55.6) | 6 (11.3) |
Weight loss | 25 (56.8) | 3 (33.3) | 28 (52.8) |
Sleep disordersc | 17 (38.6) | 4 (44.4) | 21 (39.6) |
Mood disordersd | 19 (43.2) | 3 (33.3) | 22 (41.5) |
Gastrointestinal symtomse | 27 (61.4) | 4 (44.4) | 31 (58.5) |
Seizures | 5 (11.4) | 2 (22.2) | 7 (12.2) |
Dysautonomiaf | 17 (38.6) | 3 (33.3) | 20 (37.7) |
CSF elevated white cell account | 16/33 (48.5) | 2 (22.2) | 18/42 (42.9) |
CSF elevated proteins | 8/19 (42.1) | 4 (44.4) | 12/28 (42.9) |
Brain MRI abnormalities | 9 (20.5) | 8 (88.9) | 17 (32.1) |
Brain MRI specific changes | 1 (2.3) | 7 (77.8) | 8 (14.1) |
Tumor Screening | 5 (11.4) | 2 (22.2) | 7 (13.2) |